AI Article Synopsis
- * Conducted from March to September 2021, the research enrolled 270 participants from a memory clinic, with 93.7% receiving the vaccine.
- * Rare adverse events were reported, and cognitive or behavioral changes post-vaccination were infrequent, suggesting vaccination is safe and should be prioritized for this population.
Article Abstract
This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JAD-220077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!